CORONAVIRUS: DIAGNOSIS AND THERAPY IN HUMANS

VolverGo back

Resultados 477 results. LastUpdate Updated on 30/11/2022 [15:45:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days



Page1/20 nextPage   results/page


COMPOSITIONS FOR TREATING SARS-COV2 INFECTION

Publication No.: EP4094755A1 30/11/2022

Applicant:

HIRSCH APOTHEKE WOLFGANG SCHOLZ E K [DE]

EP_4094756_A1

Absstract of: EP4094755A1

The present invention relates to compositions comprising hypericin and/or pseudohypericin for use in a method for treating or preventing an infection with SARS-CoV2 in a human subject in need thereof. The present invention further relates to (mouth wash, gargle solution, nose spray, inhalant, lozenge, tablet, chewing gum, injection solution comprising hypericin and/or pseudohypericin.

traducir

COMPOSITIONS FOR TREATING SARS-COV2 INFECTION

Publication No.: EP4094756A1 30/11/2022

Applicant:

HIRSCH APOTHEKE WOLFGANG SCHOLZ E K [DE]

EP_4094755_A1

Absstract of: EP4094756A1

The present invention relates to compositions comprising hypericin and/or pseudohypericin for use in a method for treating or preventing an infection with SARS-CoV2 in a human subject in need thereof. The present invention further relates to (mouth wash, gargle solution, nose spray, inhalant, lozenge, tablet, chewing gum, injection solution comprising hypericin and/or pseudohypericin.

traducir

USE OF BENZOATE COMPOUND IN TREATMENT OF SARS-COV-2 INFECTIONS

Publication No.: EP4094758A1 30/11/2022

Applicant:

ACAD OF MILITARY MEDICAL SCIENCES [CN]

WO_2021147272_A1

Absstract of: EP4094758A1

Disclosed are the use of a benzoate compound as shown in formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof and/or a solvate thereof or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound in the prevention and treatment of SARS-CoV-2 infections.

traducir

COMPOSITION AND METHODS OF RNAi PROPHYLACTICS AND THERAPEUTICS FOR TREATMENT OF SEVERE ACUTE RESPIRATORY INFECTION CAUSED BY 2019 NOVEL CORONAVIRUS (2019-nCoV)

Publication No.: EP4093511A2 30/11/2022

Applicant:

SIRNAOMICS INC [US]

KR_20220151612_PA

Absstract of: WO2021151096A2

Compositions and methods for development of potent siRNA therapeutics for prevention and treatment of Corona Virus (2019-nCoV; COVID-19) infections are provided. The compositions include a pharmaceutical composition comprising siRNA cocktails that target critical viral genes and pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Administration methods for prevention and treatment are provided, including airway instillation, subcutaneous injections and nebulizer aerosolization.

traducir

USE OF INTERFERON IN PREPARING DRUG FOR PREVENTING CORONAVIRUS INFECTION OR PREVENTING DISEASE CAUSED BY CORONAVIRUS INFECTION

Publication No.: EP4094774A1 30/11/2022

Applicant:

SHANGHAI GANYI MEDICAL BIOTECHNOLOGY INC [CN]
MENG ZHONGJI [CN]
LL HAI [CN]

Absstract of: EP4094774A1

Disclosed are a use of an interferon in preparing a drug for preventing novel coronavirus SARS-CoV-2 infection or a disease COVID-19 caused by the novel coronavirus infection, and a drug for preventing novel coronavirus infection or preventing a disease COVID-19 caused by the novel coronavirus infection.

traducir

METHOD OF BREATH SCREENING OF VIRAL INFECTION

Publication No.: CA3160350A1 25/11/2022

Applicant:

TEKNOSCAN SYSTEMS INC [CA]

Absstract of: CA3160350A1

An apparatus for detecting Covid-19 infection in a subject, the apparatus comprising (a) a sampling apparatus for collecting a breath sample from a subject (b) An analyzer, comprising an ion mobility spectrometer (IIVIS), for receiving the sample from the sampling apparatus and for determining the presence in the sample of Volatile Organic Compounds (VOCs) indicative of Covid-19, the VOCs comprising at least three compounds selected from the group consisting of C1-C3 alcohols, C2-C8 aldehydes, C3-C4 ketones and C4-C6 alkyl esters.

traducir

METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT

Publication No.: US2022370589A1 24/11/2022

Applicant:

TOPELIA AUSTRALIA PTY LTD ACN 652 771 670 [AU]

Absstract of: US2022370589A1

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection by administration of an antibiotic and/or an anti-viral drugs and a vaccine directed to a causative agent of the infection and/or an attenuated and/or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of “vaccine breakthrough infections” after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and/or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of

traducir

Coronavirus detection

Publication No.: AU2021240470A1 24/11/2022

Applicant:

DIAGNOSTICS FOR THE REAL WORLD LTD

WO_2021191795_A1

Absstract of: AU2021240470A1

Methods for detecting nucleic acid of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are described. The methods comprise amplifying nucleic acid of a sample, or amplifying nucleic acid derived from nucleic acid of the sample, by an isothermal amplification reaction using a forward nucleic acid amplification primer and a reverse nucleic acid amplification primer, wherein each nucleic acid amplification primer hybridises specifically to nucleic acid sequence that is conserved in SARS-CoV-2 nucleic acid, but not in other human coronavirus nucleic acid, or the complement thereof. The methods are particularly useful for point-of-care (ROC) testing. Kits, primers, probes, sets of primers, sets of oligonucleotides, and oligonucleotides, and their use in the methods are also described.

traducir

ELECTROCHEMICAL DIAGNOSTIC SYSTEM AND METHODS OF OBTAINING AND USING ELECTROCHEMICAL DIAGNOSTIC RESULTS

Publication No.: WO2022246292A1 24/11/2022

Applicant:

PERSOWN INC [US]

Absstract of: WO2022246292A1

Devices, systems, kits, methods, and techniques are described herein that are useful for to detecting analytes in body or test fluids using a functionalized electrochemical test strip and potentiostatic measurements, allowing for quickly (within 5 minutes) identifying whether or not an individual has a particular disease or condition, such as infection by SARS-CoV-2 or a variant or vaccine-induced immunity or natural immunity to infection by SARS-CoV-2 or a variant, or whether an individual would benefit from a vaccine booster. The test results can be used for applications including facilitating or controlling access at events, venues, or transportation systems, or generating exposure notifications. The electrodes include a SAM linked to the capture agents via a click chemistry based linker. There's also a charged passivation component (e.g. thiolated PEG) in the SAM. Charged glycosaminoglycans in the SAM contribute to anti-fouling and improving the sensitivity of the device.

traducir

VIRAL STRAIN SEROLOGY ASSAYS

Publication No.: WO2022246215A1 24/11/2022

Applicant:

MESO SCALE TECHNOLOGIES LLC [US]
US HEALTH [US]

Absstract of: WO2022246215A1

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention further provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

traducir

ASSAYS FOR VIRAL STRAIN DETERMINATION

Publication No.: WO2022246213A1 24/11/2022

Applicant:

MESO SCALE TECHOLOGIES LLC [US]
US HEALTH [US]

Absstract of: WO2022246213A1

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The inventor further provides methods and kits for detecting one or more antibody biomarkers in a sample.

traducir

CORONAVIRUS VACCINE SUITABLE FOR ELDERLY INDIVIDUALS

Publication No.: WO2022244831A1 24/11/2022

Applicant:

OKINAWA INST SCIENCE & TECH SCHOOL CORP [JP]

Absstract of: WO2022244831A1

The present invention provides a vaccine or an immunogenic composition that can be useful in an elderly human subject.

traducir

TAQ-NEQSSB POLYMERASE, THE METHOD OF ITS OBTAINING, RECOMBINANT PLASMID, PRIMERS, AND APPLICATION OF THE POLYMERASE.

Publication No.: WO2022245230A1 24/11/2022

Applicant:

INST BIOTECHNOLOGII I MEDYCYNY MOLEKULARNEJ [PL]

Absstract of: WO2022245230A1

The subject of the invention is a TaqPol-NeqSSB polymerase and its cloning method. Furthermore, the subject of the invention is an isolated recombinant plasmid, primers, and the application of the polymerase to replicate specific sequences of the SARS CoV-2 virus.

traducir

SARS-COV-2 SPIKE PROTEIN ANTIBODIES

Publication No.: WO2022245859A1 24/11/2022

Applicant:

CURIA IP HOLDINGS LLC [US]

US_2022372114_PA

Absstract of: WO2022245859A1

The present disclosure provides antibodies that bind to the SARS-CoV-2 spike protein, as well as compositions containing the same, and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.

traducir

PROTEIN ANTIGEN-BINDING MOLECULES

Publication No.: WO2022245288A1 24/11/2022

Applicant:

NAT UNIV SINGAPORE [SG]

Absstract of: WO2022245288A1

The present disclosure provides antigen-binding molecule capable of binding to a sarbecovirus spike protein from two or more different sarbecovirus. Nucleic acids, expression 5 vectors, and cells for making and using the same. In particular antigen-binding molecules such as neutralising antibodies capable of inhibiting interaction between the sarbecovirus spike protein and ACE2, thus behaving as antagonists of infection of ACE2-expressing cells by the sarbecovirus. Antigen-binding molecules described herein are provided with a combination of advantageous properties over known SARS-CoV-2 antibodies.

traducir

SARS-CORONAVIRUS 2 (SARS-COV-2) SPIKE PROTEIN SUBUNIT VACCINES

Publication No.: WO2022246449A1 24/11/2022

Applicant:

UNIV KANSAS STATE [US]

Absstract of: WO2022246449A1

A new species of coronavirus, SARS-CoV-2, is the cause of a worldwide pandemic and has resulted in hundreds of thousands of deaths. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions to reduce the severity of, incidence of and transmissibility of SARS-CoV-2.

traducir

METHODS AND COMPOSITIONS FOR CORRECTION OF AUTONOMIC DYSFUNCTIIONS

Publication No.: WO2022246186A1 24/11/2022

Applicant:

DRISCOLL DIANA [US]

US_2022370382_PA

Absstract of: WO2022246186A1

The present invention includes compositions and methods for treating certain conditions, the composition at least two active agents selected from: a choline compound; a cholinergic agonist; an acetylcholinesterase inhibitor (also referred to as a cholinesterase inhibitor); and a carnitine, in an amount effective to treat at least one of a connective tissue disorder, compression of or damage to any portion of a preganglionic or postganglionic vagus nerve, autonomic neuropathy, post-viral and post-infective autonomic dysfunction, post-traumatic autonomic dysfunction, physical trauma or mental/emotional trauma, post-traumatic stress disorder (PTSD), a genetic disorder of an acetylcholine cycle, inflammatory autonomic dysfunction, post-COVID ("Long-haulers") or Post-Acute Sequelae SARS-CoV-2, or inflammatory Postural Orthostatic Tachycardia Syndrome (POTS).

traducir

ANTIBODY-BASED ANTIVIRUS COMPOSITIONS AND METHODS OF USE

Publication No.: WO2022246116A2 24/11/2022

Applicant:

ACHELOIS BIOPHARMA INC [US]

Absstract of: WO2022246116A2

Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus. Further provided herein are antibody-based antiviruses for treating a viral infection (e.g., SARS-CoV-2).

traducir

MICRONEEDLE VACCINE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

Publication No.: WO2022246144A1 24/11/2022

Applicant:

MEDIGEN VACCINE BIOLOGICS CORP
VAXESS TECH INC [US]

Absstract of: WO2022246144A1

The present invention relates to a microneedle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to a microneedle vaccine having a recombinant SARS-CoV-2 S protein and providing a sustained release of the recombinant SARS-CoV-2 S protein in a subject.

traducir

COMPOSITION FOR TREATMENT OF COVID-19 COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT

Publication No.: WO2022245089A1 24/11/2022

Applicant:

SHAPERON INC [KR]

Absstract of: WO2022245089A1

The present invention relates to a composition for treatment of COVID-19, comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. In particular, the use of a pharmaceutically acceptable salt of TDCA was found to have an effect of treating clinical symptoms caused by a SARS-CoV-2 infection and early full recovery through alleviating inflammation and suppressing inflammatory cytokines. Thus, TDCA or a pharmaceutically acceptable salt thereof may be used as an active ingredient of a composition for preventing or treating lower respiratory tract infections including COVID-19.

traducir

T CELL EPITOPE PEPTIDE DERIVED FROM SARS-CoV-2

Publication No.: WO2022244891A1 24/11/2022

Applicant:

UNIV SAPPORO MEDICAL [JP]
NATIONAL UNIV CORPORATION ASAHIKAWA MEDICAL UNIV [JP]
MEDICAL & BIOLOGICAL LABORATORIES CO LTD [JP]

Absstract of: WO2022244891A1

An antigen peptide which contains at least five continuous amino acid residues contained in the amino acid sequence represented by SEQ ID NO: 52, has an activity of inducing a cytotoxic T cell and/or a helper T cell, and can induce the cellular immunity against SARS-CoV-2.

traducir

BIOMARKER FOR INFECTIOUS DISEASE

Publication No.: WO2022244789A1 24/11/2022

Applicant:

UNIV TOHOKU [JP]
BIO XCELERATOR INC [JP]

Absstract of: WO2022244789A1

The present invention is a biomarker which is a sulfur metabolite and is used for the diagnosis of an infectious disease. In the present invention, the sulfur metabolite may be present in exhaled breath. In this case, the sulfur metabolite can be detected from a concentrated solution of the exhaled breath. Provided is a biomarker for an infectious disease, the biomarker including: a biomarker for the diagnosis of an infection by a bacterium or a virus, particularly the diagnosis of the novel coronavirus infectious disease (COVID-19); a biomarker for the diagnosis of community-acquired pneumonia, particularly the diagnosis of pneumonia such as interstitial pneumonia caused by the novel coronavirus infectious disease and alveolar pneumonia; and a biomarker for the diagnosis of worsening caused by an infection, particularly the diagnosis of the risk of the transition to a severe stage in the novel coronavirus infectious disease. Also provided is a diagnosis system for detecting a biomarker for infection diagnosis use which comprises a sulfur metabolite from exhaled breath, the diagnosis system being used for the determination of an infection, particularly the diagnosis of the novel coronavirus infection.

traducir

ARTIFICIAL GENE N1NEW FOR ENCODING THE NUCLEOCAPSID PROTEIN OF THE CORONAVIRUS SARS-COV-2, AND RECOMBINANT PLASMID PET-28A-N1NEW FOR EXPRESSING SAID ARTIFICIAL GENE

Publication No.: WO2022245258A1 24/11/2022

Applicant:

THE FEDERAL STATE UNITARY ENTERPRISE\u201CTHE SAINT PETERSBURG SCIENT RESEARCH INSTITUTE OF VACCIN [RU]

RU_2762962_C1

Absstract of: WO2022245258A1

The invention relates to biotechnology and immunology. Proposed are a gene that allows the production of an artificial protein having immunogenic properties with respect to SARS-CoV-2, a plasmid containing said gene, as well as the artificial protein itself, which is obtained using an E.coli cell line modified by said plasmid. The recombinant protein obtained has immunogenic properties with respect to SARS-CoV-2 and can be used as an active substance for producing a vaccine against SARS-CoV-2.

traducir

NOVEL CORONAVIRUS SARS-COV-2 MUTANT VACCINE AND APPLICATION

Publication No.: WO2022242649A1 24/11/2022

Applicant:

LIVZON MABPHARM INC [CN]

CN_115368468_A

Absstract of: WO2022242649A1

The present invention relates to a novel coronavirus SARS-CoV-2 mutant vaccine and an application. The vaccine comprises a fusion protein, and the fusion protein comprises: (1) an interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2 or a functional fragment thereof; and (3) an immunoglobulin Fc region. The mutant vaccine of the present invention has a long-acting effect, is beneficial to industrial production, is equivalent to normal IFN in activity, is higher in immunogenicity and neutralizing antibody titer, can increase the defense capability against a mutant strain, and can be used as a new generation of mutant vaccine drugs for resisting epidemic spreading of novel coronavirus.

traducir

LACTOBACILLUS PLANTARUM AND USE THEREOF IN PREPARATION OF COVID-19 VACCINE IMMUNOPOTENTIATOR

Nº publicación: WO2022242446A1 24/11/2022

Applicant:

SHANGHAI PUBLIC HEALTH CLINICAL CT [CN]

CN_113308396_A

Absstract of: WO2022242446A1

Disclosed in the present invention is a strain of Lactobacillus plantarum guanke, wherein the strain has the deposit number CGMCC NO. 21720, was deposited on 22 January, 2021, has the classification name Lactobacillus plantarum guanke, and was deposited in the China General Microbiological Culture Collection Center. The strain provided in the present invention can significantly improve the neutralizing antibody titer in serum carrying SARS-CoV-2 and prolong the protection time. Further provided in the present invention is the use of the strain in the preparation of a vaccine immunopotentiator.

traducir

Page1/20 nextPage results/page

punteroimgGo back